Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.3%

1 terminated/withdrawn out of 16 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

19%

3 trials in Phase 3/4

Results Transparency

0%

0 of 13 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
8(53.3%)
Phase 2
4(26.7%)
Phase 3
3(20.0%)
15Total
Phase 1(8)
Phase 2(4)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT06510816Phase 3Active Not Recruiting

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Role: lead

NCT07424235Completed

Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natural History Cohort

Role: collaborator

NCT07020819Phase 3Recruiting

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

Role: lead

NCT04701164Phase 3Completed

Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

Role: lead

NCT04569435Phase 2Completed

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT05521269Phase 1Completed

Dose Study of ANX1502 in Healthy Volunteers

Role: lead

NCT05780515Phase 1Completed

A Study of ANX009 in Adult Participants With Lupus Nephritis

Role: lead

NCT04656561Phase 2Completed

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

Role: lead

NCT05288881Phase 1Completed

Single Ascending Dose Study of ANX105

Role: lead

NCT04691570Phase 2Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Role: lead

NCT04514367Phase 2Completed

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

Role: lead

NCT04535752Phase 1Completed

A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

Role: lead

NCT04035135Phase 1Completed

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Role: lead

NCT03488550Phase 1Completed

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

Role: lead

NCT03010046Phase 1Terminated

Single Dose Study of ANX005 in Healthy Volunteers

Role: lead

NCT04188015Phase 1Completed

Study of ANX007 in Participants With Primary Open-angle Glaucoma

Role: lead

All 16 trials loaded